PriceTargets.com logo

TC Biopharm - TCBP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 324.53%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.12 As of 03/24/2023 01:00 AM ET
▼ -0.19 (-8.23%)

This chart shows the closing price for TCBP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TC Biopharm Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TCBP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TCBP

Analyst Price Target is $9.00
▲ +324.53% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for TC Biopharm in the last 3 months. The average price target is $9.00, with a high forecast of $9.00 and a low forecast of $9.00. The average price target represents a 324.53% upside from the last price of $2.12.

This chart shows the closing price for TCBP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in TC Biopharm.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2023HC WainwrightInitiated CoverageBuy$9.00Low
(Data available from 3/26/2018 forward)

News Sentiment Rating

-0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/27/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/25/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/25/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/24/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
TC Biopharm logo
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Read More

Today's Range

Now: $2.12
Low: $2.03
High: $2.20

50 Day Range

MA: $4.72
Low: $2.12
High: $7.45

52 Week Range

Now: $2.12
Low: $2.03
High: $106.50

Volume

72,104 shs

Average Volume

140,231 shs

Market Capitalization

$2.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of TC Biopharm?

The following Wall Street analysts have issued reports on TC Biopharm in the last year: HC Wainwright.
View the latest analyst ratings for TCBP.

What is the current price target for TC Biopharm?

1 Wall Street analysts have set twelve-month price targets for TC Biopharm in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 324.5%. HC Wainwright has the highest price target set, predicting TCBP will reach $9.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $9.00 for TC Biopharm in the next year.
View the latest price targets for TCBP.

What is the current consensus analyst rating for TC Biopharm?

TC Biopharm currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TCBP will outperform the market and that investors should add to their positions of TC Biopharm.
View the latest ratings for TCBP.

What other companies compete with TC Biopharm?

Other companies that are similar to TC Biopharm include Kiromic BioPharma, Brickell Biotech, Fresh Tracks Therapeutics, Brookline Capital Acquisition and Windtree Therapeutics. Learn More about companies similar to TC Biopharm.

How do I contact TC Biopharm's investor relations team?

The company's listed phone number is 44-14-1433-7557 and its investor relations email address is [email protected] The official website for TC Biopharm is www.tcbiopharm.com. Learn More about contacing TC Biopharm investor relations.